|Bid||2.6100 x 1000|
|Ask||2.6200 x 1000|
|Day's Range||2.5000 - 2.6700|
|52 Week Range||1.9000 - 6.6000|
|Beta (5Y Monthly)||1.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.75|
NantHealth, Inc. (NASDAQ-GS: NH), a provider of enterprise solutions that help transform complex data into actionable insights, today announced the signing of a new financing that will include the issuance of $137.5 million aggregate principal amount of new senior unsecured convertible notes due 2026 (the "2026 Notes") in a private transaction, with the common stock that may be issued upon a conversion to be registered under the Securities Act of 1933, as amended (the "Securities Act"). As part of the transaction, the company will enter into an agreement to extend the maturity of its existing subordinated note to October 2026. The company intends to use the proceeds of the 2026 Notes to retire its existing convertible notes due December 2021 (the "2021 Notes") and further invest in initiatives to grow its business.
NantHealth, Inc. (NASDAQ: NH), today announced a new population health management product that pulls together disparate data to provide a full 360-degree picture of the patient while enabling better workflow between providers, payers, hospitals/healthcare networks and patients in one platform. This new product reduces avoidable costs and increases patient and provider satisfaction.
Controversial billionaire scientist Dr. Patrick Soon-Shiong discusses COVID-19 vaccine efforts.